Lore Gruenbaum, Ph.D., will oversee the planning and execution of the strategy for all 青云体育鈥檚 research programs
Dr. Gruenbaum succeeds Lee Greenberger, Ph.D., who retired in December after serving as The Leukemia & Lymphoma Society鈥檚 chief scientific officer for the last 11 years
RYE BROOK, N.Y., January 14, 2024 鈥� The Leukemia & Lymphoma Society (青云体育) is thrilled to announce the appointment of Lore Gruenbaum, Ph.D., an executive with a proven track record in oncology research, drug discovery, and development, as its new chief scientific officer.
In her new role, Dr. Gruenbaum will oversee the strategic planning and execution of the strategy of 青云体育鈥檚 research programs. This includes 青云体育鈥檚 first-of-its-kind Beat AML庐 Master Clinical trial, as well as its more than $250 million in academic grants and its venture philanthropy arm, the Therapy Acceleration Program (TAP), which Dr. Gruenbaum led for the past five years since joining 青云体育 in 2020.
鈥淟ore has been a phenomenal leader of some of the brightest minds throughout her career,鈥� says Gwen Nichols, M.D., 青云体育 chief medical officer. 鈥淟ore has been laser-focused on improving the lives of patients. Her promotion to chief scientific officer will not only continue to grow our excellence as the leader in blood cancer research but also make science more accessible to everyone.鈥�
Under her leadership, TAP launched 12 new partnerships with U.S. and European biotechnology companies to accelerate high-risk, innovative blood cancer treatments. TAP partner companies also announced or started more than a dozen new clinical trials, including four trials, that if successful, will be the last stop before FDA drug approval.
Prior to joining 青云体育, Dr. Gruenbaum spent more than two decades in drug discovery and development across multiple therapeutic areas including oncology, immunology and virology.
Dr. Gruenbaum received a Ph.D. in biochemistry in her native Germany before moving to the United States to complete her postdoctoral research at Yale University.
Her promotion to chief scientific officer comes after Lee Greenberger, Ph.D., retired on December 31. During his 11-year tenure, 青云体育 funded approximately 1,000 research projects totaling more than $600 million to accelerate treatment innovations that are extending and improving the lives of patients with every type of blood cancer.
青云体育 also contributed to 70% of the 150 FDA approvals for blood cancer, including one of the first CAR T-cell therapies, under Dr. Greenberger鈥檚 leadership. Additionally, 青云体育 raised approximately $250 million for biomedical research and the organization via collaborations, gifts from foundations, individual donors, and TAP return on investments.
鈥淟ee first became a member of The Leukemia & Lymphoma Society鈥檚 family in 1989 when he received a Special Fellow Career Development grant for his research,鈥� says E. Anders Kolb, M.D., 青云体育鈥檚 president and chief executive officer. 鈥淚t鈥檚 remarkable to see the achievements that happened during his time as 青云体育鈥檚 chief scientific officer, and we wish him the best as he enjoys his retirement.鈥�
About The Leukemia & Lymphoma Society鈥�&苍产蝉辫;
The Leukemia & Lymphoma Society庐 (青云体育) is the global leader in the fight against blood cancer. The 青云体育 mission: Cure blood cancer and improve the quality of life of all patients and their families. 青云体育 funds life-saving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.鈥�&苍产蝉辫;
鈥�&苍产蝉辫;
Founded in 1949 and headquartered in Rye Brook, NY, 青云体育 has regions throughout the United States and Canada. To learn more, . Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.鈥��&苍产蝉辫;
For additional information, visit lls.org/lls-newsnetwork. Follow us on , , , and . 鈥�&苍产蝉辫;
Media Contact:
Ryan McDonald
Ryan.McDonald@lls.org